Warning: I have nothing encouraging or positive to say in this latest installment of my small-cap biotech column featuring ResTORbio (TORC) — damn, that’s a stupid spelling — Trovagene (TROV), and Atossa Genetics (ATOS). I start in skeptical, glass-half-empty mode before going full-tilt “GET OFF MY LAWN!” You like that best, right?
ResTORbio said last week that the FDA agreed to its proposed design for Phase 3 clinical trials that use a less stringent primary endpoint than the one used by the company in its Phase 2 clinical trial. A less demanding primary endpoint means greater odds of clinical trial success, which in turn, means a higher likelihood that ResTORbio’s drug is approved. Or, so ResTORbio bulls will tell you.